Cardiovascular disease (CVD) remains a paramount global health challenge, representing the leading cause of mortality worldwide. Effectively mitigating its devastating impact hinges significantly on the ability to accurately identify individuals at heightened risk before a major cardiac event occurs. This imperative has driven the development of sophisticated diagnostic tools and risk stratification models designed to peer into a patient’s future cardiovascular health. Among these, coronary artery calcium (CAC) scoring has emerged as a widely utilized imaging technique, providing a visual proxy for arterial plaque burden. However, recent rigorous research from Northwestern Medicine is now refining our understanding of CAC’s optimal application, suggesting its most profound utility may be concentrated within a specific patient demographic rather than across the entire adult population.
For decades, clinicians have relied on various methods to gauge a person’s propensity for heart attack or stroke. These methods range from traditional risk factor assessment, encompassing age, sex, cholesterol levels, blood pressure, and smoking status, to more advanced imaging. The PREVENT (Predicting Risk of CVD Events) calculator, a modern iteration from the American Heart Association, exemplifies the former approach. This sophisticated algorithm synthesizes readily available clinical data to generate personalized 10-year and 30-year projections of an individual’s likelihood of experiencing an atherosclerotic cardiovascular disease (ASCVD) event. It serves as a foundational tool, guiding primary care physicians and cardiologists in making initial assessments and recommending preventive strategies.
Complementing these algorithmic predictions are imaging modalities like the coronary artery calcium scan. This non-invasive computed tomography (CT) procedure specifically targets the heart’s major arteries—the coronaries—to detect and quantify calcified plaque. Atherosclerosis, the underlying disease process for most cardiovascular events, involves the gradual buildup of fatty plaques within arterial walls. Over time, these plaques can harden and calcify, making them visible on a CT scan. The resulting CAC score, typically ranging from zero to thousands, directly correlates with the amount of detectable calcified plaque: a higher score indicates a greater atherosclerotic burden and, generally, an elevated risk of future cardiac complications. The scan’s relative speed and decreasing cost have contributed to its growing popularity as a screening tool.
Despite its increasing adoption, the precise role of routine CAC screening in a comprehensive cardiovascular prevention strategy has been a subject of ongoing debate. The Northwestern Medicine study, published on August 26 in the prestigious journal JAMA, sought to clarify this by rigorously comparing the predictive power of CAC scores against the established PREVENT algorithm. The investigation, led by Dr. Nilay Shah, an assistant professor of medicine in the division of cardiology at Northwestern University Feinberg School of Medicine, and his colleagues, leveraged data from a robust, long-term observational study.
The researchers meticulously analyzed information from over 6,000 adult participants, aged between 45 and 79 years, who were part of the Multi-Ethnic Study of Atherosclerosis (MESA). This renowned epidemiological study is specifically designed to investigate the prevalence, correlates, and progression of subclinical cardiovascular disease. At the outset of the MESA study, each participant underwent both a coronary artery calcium scan to determine their baseline CAC score and an assessment using the PREVENT calculator to estimate their 10-year cardiovascular event risk. Crucially, the research team then embarked on a decade-long follow-up, diligently tracking the actual incidence of major cardiovascular events, such as heart attacks and strokes, within this cohort.
Upon analyzing the extensive dataset, the Northwestern team made a pivotal observation. For the broad study population as a whole, integrating the coronary artery calcium score into the risk assessment paradigm provided only a modest, incremental improvement in predicting future cardiovascular events when compared to the predictions generated by the PREVENT calculator alone. This finding was quantified by a slight increase in the model’s discrimination — a statistical measure of its ability to differentiate between individuals who would and would not experience a cardiovascular event. The discrimination metric rose marginally from 0.73 with PREVENT alone to 0.75 when CAC scores were incorporated. This suggests that while CAC scores do add some information, their broad, indiscriminate application might not yield substantial gains for everyone.
However, the narrative shifted dramatically when the researchers narrowed their focus to a specific subgroup: individuals initially categorized by the PREVENT calculator as being at "borderline" or "intermediate" risk. This group typically encompasses those with an estimated 10-year cardiovascular disease risk ranging from 3% to 9%. For these patients, the inclusion of a CAC score proved to be profoundly impactful, leading to a much more significant enhancement in the accuracy of predicting future cardiovascular events. Dr. Shah emphasized this critical nuance, stating that for individuals teetering on the edge of moderate risk, knowing their calcium score can be a decisive factor, either confirming a lower actual risk or revealing a higher, previously underestimated one. This refined stratification empowers clinicians to make more informed and personalized treatment decisions.
The implications of these findings for clinical practice are substantial, particularly in the realm of personalized medicine and resource allocation. Cardiovascular disease affects approximately 10% of U.S. adults aged 30-79, and while it remains the leading cause of death, a significant proportion of heart attacks and strokes are preventable. The key lies in identifying who stands to benefit most from preventive interventions. For instance, statins, a class of drugs renowned for their cholesterol-lowering properties and proven efficacy in reducing cardiovascular risk, are a cornerstone of prevention. Accurately pinpointing patients who truly require statin therapy—and those who do not—is crucial for optimizing health outcomes and avoiding unnecessary medication.
The study underscores potential downsides of indiscriminate CAC scanning. For patients already deemed to be at low risk by robust calculators like PREVENT, adding a calcium scan might offer minimal, if any, clinical benefit. Such unnecessary testing carries inherent risks, including exposure to ionizing radiation, however small, and contributes to increased healthcare costs. Furthermore, a positive, albeit low, calcium score in a low-risk individual could lead to unwarranted anxiety, additional follow-up tests, and potentially the initiation of treatments that are not truly necessary. Conversely, for individuals already at very high risk, who are unequivocally recommended to start statin therapy based on their clinical profile, a CAC scan might also be superfluous. In these cases, the scan is unlikely to alter the fundamental treatment recommendation, making it an additional expense without a change in management.
Dr. Shah articulated this perspective, highlighting that "Routinely using a calcium scan in people who are at low risk may result in unnecessary radiation exposure, testing and costs with unclear clinical benefits." He further clarified, "Using calcium scans in people who are at high risk is likely to result in unnecessary testing because these individuals are recommended to start a statin regardless of what the calcium scan shows." This targeted approach ensures that valuable diagnostic resources are deployed where they can provide the most meaningful clinical impact, aligning with principles of value-based healthcare.
The research also implicitly validates the robust performance of the PREVENT calculator itself. Even without the added layer of a calcium scan, PREVENT demonstrated strong capabilities in predicting cardiovascular risk, affirming its utility as a primary screening tool. The study, therefore, positions CAC scanning not as a replacement for comprehensive risk calculators, but as a powerful adjunct, especially when the initial risk assessment falls into an ambiguous zone.
While the Northwestern Medicine study provides invaluable insights, the researchers acknowledge that further investigation is warranted to fully delineate the optimal application of CAC scoring. Additional studies are needed to explore how calcium scores improve PREVENT estimates in specific, often higher-risk populations, such as South Asian and Filipino adults, where cardiovascular disease patterns can differ. Moreover, the MESA study participants were aged 45 to 79 at the study’s inception, meaning more research is required to understand the utility and implications of CAC screening in younger individuals.
In conclusion, this landmark research by Northwestern Medicine marks a significant step forward in refining cardiovascular risk assessment. By meticulously identifying the specific patient population—those at borderline or intermediate risk—who derive the greatest benefit from coronary artery calcium scans, the study provides a clearer roadmap for clinicians. It advocates for a more strategic, precision-guided approach to screening, ensuring that this valuable diagnostic tool is utilized effectively and efficiently, ultimately leading to more personalized preventive care and improved patient outcomes in the ongoing battle against heart disease.
Other Northwestern co-authors on the study include Xiaoning Huang, Lucia Petito, Norrina Allen, Dr. Philip Greenland, and Dr. Sadiya Khan. The research was supported by grants from the American Heart Association and the National Heart, Lung, and Blood Institute.
About the Author
